Short Interest in Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) Expands By 314.4%

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) saw a large growth in short interest during the month of May. As of May 15th, there was short interest totaling 11,113 shares, a growth of 314.4% from the April 30th total of 2,682 shares. Currently, 0.0% of the shares of the company are sold short. Based on an average daily volume of 14,125 shares, the short-interest ratio is presently 0.8 days.

Santen Pharmaceutical Stock Performance

Shares of SNPHY stock opened at $11.72 on Friday. The company has a market capitalization of $3.78 billion and a price-to-earnings ratio of 0.10. The company has a 50-day simple moving average of $11.22 and a 200 day simple moving average of $10.85. Santen Pharmaceutical has a 52 week low of $9.22 and a 52 week high of $12.68.

Analyst Ratings Changes

Separately, Zacks Research upgraded shares of Santen Pharmaceutical to a “hold” rating in a research note on Monday, April 13th. One investment analyst has rated the stock with a Hold rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Hold”.

Santen Pharmaceutical Company Profile

Santen Pharmaceutical Co, Ltd. is a Japan?based specialty pharmaceutical company focused exclusively on ophthalmology. Headquartered in Osaka, Santen engages in the research, development, manufacture and marketing of prescription and over?the?counter products for the diagnosis and treatment of eye diseases. Its core product portfolio includes therapies for glaucoma, dry eye, retinal disorders, uveitis and post?operative care, as well as surgical equipment and diagnostic agents designed to support comprehensive eye care.

With roots tracing back to the late 19th century, Santen has grown from a domestic manufacturer to a global ophthalmic specialist.